TMCnet News
Research and Markets: Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class InnovationDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/z6pd5l/frontier_pharma) has announced the addition of the "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" report to their offering. Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including afety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful. Scope:
Key Topics Covered: 1 Table of Contents 2 The Case for Innovation 3 Clinical and Commercial Landscape 4 Assessment of Psoriasis Pipeline and Innovation 5 First-in-Class Target (News - Alert) and Pipeline Program Evaluation 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/z6pd5l/frontier_pharma
|